Navigation Links
Foundation Venture Capital Group Invests in Company Working to Protect Healthy Tissue During Cancer Treatment
Date:11/24/2008

NEW BRUNSWICK, N.J., Nov. 24 /PRNewswire-USNewswire/ -- James M. Golubieski, president of Foundation Venture Capital Group, LLC, a New Jersey Health Foundation affiliate, announced today that the company has made a $500,000 commitment to Longevica Pharmaceuticals, Inc., a company involved in developing kinase inhibitors that may keep normal cells healthy during chemotherapy or radiation treatments.

The company is a start-up at the University of Medicine and Dentistry of New Jersey.

"Despite the tremendous progress in chemotherapy and radiation use to treat cancer patients, most of the drugs available today are extremely toxic, not only killing cancer cells but also killing normal cells," explained Alexey Ryazanov, PhD, founder and president of Longevica. "Our company is working to develop approaches to help protect normal tissue during chemotherapy and radiation treatment."

Longevica scientists discovered that if the EF2 kinase (a protein involved in the regulation of protein synthesis in human cells) can be rendered inactive, normal cells could be protected from dying during chemotherapy and radiation treatment. Not only does this process protect normal tissues from dying, says Dr. Ryazanov, but it also renders the cancer-killing treatment more effective.

"The work of Dr. Ryazanov and the scientists at Longevica is so exciting because currently, there is no such therapy available," explained George F. Heinrich, MD, vice chair and CEO of Foundation Venture Capital Group. "A breakthrough in the use of this kinase could positively affect millions of people undergoing cancer treatments. We are proud that Foundation Venture Capital Group is able to help move Longevica's research to the next level of study."

In addition to helping cancer patients undergoing treatment, preliminary studies also indicate the same drug can be used to help patients who have had strokes by protecting cells and tissues from cell death in the heart and brain. It may also prevent the progressive loss of neurons in patients with Alzheimer's or Parkinson's disease

Foundation Venture Capital Group was founded in 2006 to invest in commercially viable new start-up companies developing technology at the University of Medicine & Dentistry of New Jersey. Longevica Pharmaceuticals, Inc., is its third investment.


'/>"/>
SOURCE Foundation Venture Capital Group, LLC
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. National Patient Safety Foundation Partners with Vocera Communications
2. R. P. Simmons Family Foundation Pledges $2 Million for New Childrens Hospital of Pittsburgh of UPMC Campus
3. Patient Advocate Foundation Launches Program to Help Uninsured Virginians with Chronic, Debilitating and Life-Threatening Illness Access Quality Healthcare
4. AIDS Healthcare Foundation Applauds City Commissioners Support of Diversity, Urges Call for Mayors Resignation
5. National Osteoporosis Foundation Teams Up With Ladies Home Journal Magazine to Launch a 10-city Mall Walk Tour
6. Judge Rules That Florida Disease Management Program Serving 8,000 HIV/AIDS Patients Should Be Re-bid, Says AIDS Healthcare Foundation
7. The Tug McGraw Foundation Announces 2007 Fundraising Gala
8. The Arthur M. Blank Family Foundation Pushes for Pre-K Expansion in Georgia
9. Cipla, Tell the Truth; AIDS Healthcare Foundation Launches New Ad Campaign
10. Survey From The Partnership and MetLife Foundation Reveals Important Role Todays Grandparents Play in Teens Lives
11. Exceptional Childrens Foundation Merger with Kayne Eras Center Creates One of States Most Comprehensive Nonprofits Serving the Disabled
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... (PRWEB) , ... May 25, 2016 , ... There was a time when tampons and ... going with the flow and turning to menstrual cups, like Lunette . To make ... is introducing their new anthem in this catchy video ! , It’s easy ...
(Date:5/25/2016)... ... 25, 2016 , ... Dr. Travis Schwarz is an experienced dentist who leads ... MO 63366. He serves patients of all ages with a full menu of dental ... is reflected in the superior patient reviews that he has consistently earned during his ...
(Date:5/25/2016)... , ... May 25, 2016 , ... ... services and products in the developing world, is pleased to release their 2015 ... over 5 million unwanted pregnancies, almost 14,000 maternal deaths and 3.8 million unsafe ...
(Date:5/25/2016)... ... May 25, 2016 , ... ... its annual Medical and Prescription Drug survey , an employee benefits ... survey, which was conducted in December 2015, indicates that employers are turning to ...
(Date:5/25/2016)... (PRWEB) , ... May 25, 2016 , ... "FCPX LUT ... quality of your footage," said Christina Austin - CEO of Pixel Film Studios. ... can quickly and easily add stylish color grades to their footage. A LUT is ...
Breaking Medicine News(10 mins):
(Date:5/25/2016)... Deutschland und GERMANTOWN, Maryland , ... Zusammenarbeit mit Therawis bedient dringenden ...   QIAGEN N.V. (NASDAQ: ... bekannt, eine Lizenz- und Entwicklungsvereinbarung mit Therawis Diagnostics ... die Onkologie eingegangen zu sein. Ein erstes Projekt ...
(Date:5/25/2016)... 2016  Zymo Research Corp. announced today the ... materials that help researchers obtain the most accurate ... The rapid growth of the study of microbiomes ... standard methods to improve the reproducibility and quality ... at every step of the measurement process including ...
(Date:5/25/2016)... , May 25, 2016 ... Size, Share, Development, Growth and Demand Forecast to 2022 ... Insulin Pump and Others)" published by P&S Market Research, ... $9,998.3 million in 2015, and it is expected to ... on type, the insulin pump segment is expected to ...
Breaking Medicine Technology: